{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T23:27:54Z","timestamp":1792106874591,"version":"4.4.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:00:00Z","timestamp":1759363200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Deutsches Rheuma-Forschungszentrum Berlin (DRFZ)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In psoriatic arthritis (PsA), growing evidence indicates sex-specific differences regarding clinical manifestation and treatment outcomes. Research has highlighted that females may be less likely to achieve treatment targets and are more prone to discontinuing therapy, though data on sex-specific adverse events is limited. This analysis investigates sex differences in treatment outcomes, persistence, discontinuation reasons, and adverse events during first-line b\/tsDMARD therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this analysis biona\u00efve patients with PsA from the RABBIT-SpA register were included at the start of their first b\/tsDMARD. Therapy persistence was estimated using the Cox-regression adjusted for age. Descriptive analyses were used to examine and compare sex\u2013specific differences on reasons for therapy discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 457 female patients and 343 male patients were included. Females exhibited more severe joint involvement and poorer patient-reported parameters, such as higher disease activity, more pain, and greater functional limitations. In contrast, males showed more pronounced skin involvement and a higher prevalence of nail psoriasis. Females had lower treatment persistence rates, both in the overall analysis of all first-line b\/tsDMARDs and in subgroup analyses restricted to TNFi and IL17i therapies. At 12 months, 52% of females and 68% of males remained on their initial b\/tsDMARD therapy. Notable sex differences were also observed in the reasons for therapy discontinuation: males more frequently discontinued due to lack of efficacy or remission, while females more often stopped treatment due to adverse events. Our safety analysis indicated that although female patients experienced a greater number of overall adverse events, males reported serious adverse events at twice the rate.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our findings underscore the need for sex-specific treatment strategies and more comprehensive research into biological and sociocultural factors influencing therapy persistence and reasons for discontinuation in real-world settings. Tailored treatment strategies are needed with regard to biologic therapy to overcome worse therapeutic outcomes in female patients with PsA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical trial number<\/jats:title>\n                    <jats:p>Not applicable.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13075-025-03650-4","type":"journal-article","created":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T09:51:00Z","timestamp":1759398660000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Real-world sex differences in treatment persistence and reasons for discontinuation in psoriatic arthritis patients: results from the German RABBIT-SpA register"],"prefix":"10.1186","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8416-0463","authenticated-orcid":false,"given":"Lisa","family":"Lindner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2069-2190","authenticated-orcid":false,"given":"Anja","family":"Wei\u00df","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3729-0772","authenticated-orcid":false,"given":"Andreas","family":"Reich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8750-7186","authenticated-orcid":false,"given":"Frank","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9475-9362","authenticated-orcid":false,"given":"Xenofon","family":"Baraliakos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2456-4049","authenticated-orcid":false,"given":"Anne C.","family":"Regierer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,2]]},"reference":[{"issue":"3","key":"3650_CR1","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1093\/rheumatology\/kes324","volume":"52","author":"A Ogdie","year":"2013","unstructured":"Ogdie A, Langan S, Love T, Haynes K, Shin D, Seminara N, et al. Prevalence and treatment patterns of psoriatic arthritis in the UK. Rheumatology (Oxford). 2013;52(3):568\u201375.","journal-title":"Rheumatology (Oxford)"},{"key":"3650_CR2","doi-asserted-by":"publisher","first-page":"849560","DOI":"10.3389\/fimmu.2022.849560","volume":"13","author":"NL Bragazzi","year":"2022","unstructured":"Bragazzi NL, Bridgewood C, Watad A, Damiani G, McGonagle D. Sex-Based medicine Meets psoriatic arthritis: lessons learned and to learn. Front Immunol. 2022;13:849560.","journal-title":"Front Immunol"},{"issue":"4","key":"3650_CR3","doi-asserted-by":"publisher","first-page":"488","DOI":"10.3899\/jrheum.220386","volume":"50","author":"LC Coates","year":"2023","unstructured":"Coates LC, van der Horst-Bruinsma IE, Lubrano E, Beaver S, Drane E, Ufuktepe B, et al. Sex-Specific differences in patients with psoriatic arthritis: A systematic review. J Rheumatol. 2023;50(4):488\u201396.","journal-title":"J Rheumatol"},{"issue":"9","key":"3650_CR4","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/s41584-022-00810-7","volume":"18","author":"S Tarannum","year":"2022","unstructured":"Tarannum S, Leung YY, Johnson SR, Widdifield J, Strand V, Rochon P, et al. Sex- and gender-related differences in psoriatic arthritis. Nat Rev Rheumatol. 2022;18(9):513\u201326.","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"3650_CR5","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1136\/annrheumdis-2012-201357","volume":"72","author":"L Eder","year":"2013","unstructured":"Eder L, Thavaneswaran A, Chandran V, Gladman DD. Gender difference in disease expression, radiographic damage and disability among patients with psoriatic arthritis. Ann Rheum Dis. 2013;72(4):578\u201382.","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"3650_CR6","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40744-023-00535-3","volume":"10","author":"E Lubrano","year":"2023","unstructured":"Lubrano E, Scriffignano S, Fatica M, Triggianese P, Conigliaro P, Perrotta FM, et al. Psoriatic arthritis in males and females: differences and similarities. Rheumatol Ther. 2023;10(3):589\u201399.","journal-title":"Rheumatol Ther"},{"issue":"1","key":"3650_CR7","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/s13075-021-02680-y","volume":"24","author":"E Passia","year":"2022","unstructured":"Passia E, Vis M, Coates LC, Soni A, Tchetverikov I, Gerards AH, et al. Sex-specific differences and how to handle them in early psoriatic arthritis. Arthritis Res Ther. 2022;24(1):22.","journal-title":"Arthritis Res Ther"},{"key":"3650_CR8","doi-asserted-by":"crossref","unstructured":"Eder L, Gladman DD, Mease P, Pollock RA, Luna R, Aydin SZ et al. Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension. RMD Open. 2023;9(1).","DOI":"10.1136\/rmdopen-2022-002718"},{"key":"3650_CR9","doi-asserted-by":"crossref","unstructured":"Hellamand P, van de Sande MGH, \u00d8rnbjerg LM, Klausch T, Eklund KK, Relas H et al. Sex differences in the effectiveness of first-line tumor necrosis factor inhibitors in psoriatic arthritis; results from the EuroSpA Research Collaboration Network. Arthritis Rheumatol. 2023.","DOI":"10.1002\/art.42758"},{"issue":"2","key":"3650_CR10","doi-asserted-by":"publisher","first-page":"R52","DOI":"10.1186\/ar2670","volume":"11","author":"AA Saad","year":"2009","unstructured":"Saad AA, Ashcroft DM, Watson KD, Hyrich KL, Noyce PR, Symmons DP. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British society of rheumatology biologics register. Arthritis Res Ther. 2009;11(2):R52.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"3650_CR11","doi-asserted-by":"publisher","first-page":"5415","DOI":"10.1007\/s12325-023-02693-w","volume":"40","author":"B Joven","year":"2023","unstructured":"Joven B, Manteca CF, Rubio E, Raya E, P\u00e9rez A, Hern\u00e1ndez R, et al. Real-World persistence and treatment patterns in patients with psoriatic arthritis treated with Anti-IL17 therapy in spain: the PerfIL-17 study. Adv Ther. 2023;40(12):5415\u201331.","journal-title":"Adv Ther"},{"key":"3650_CR12","doi-asserted-by":"crossref","unstructured":"Koehm M, Foldenauer AC, Rossmanith T, Kellner H, Kiltz U, Burmester GR et al. Differences in treatment response between female and male psoriatic arthritis patients during IL-12\/23 therapy with or without methotrexate: post hoc analysis of results from the randomised MUST trial. RMD Open. 2023;9(4).","DOI":"10.1136\/rmdopen-2023-003538"},{"issue":"2","key":"3650_CR13","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s00393-019-0613-z","volume":"79","author":"AC Regierer","year":"2020","unstructured":"Regierer AC, Wei\u00df A, Baraliakos X, Zink A, Listing J, Strangfeld A. [RABBIT-SpA: a new disease register for axial spondyloarthritis and psoriatic arthritis]. Z Rheumatol. 2020;79(2):135\u201342.","journal-title":"Z Rheumatol"},{"issue":"1","key":"3650_CR14","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s13075-021-02563-2","volume":"23","author":"L Lindner","year":"2021","unstructured":"Lindner L, Wei\u00df A, Reich A, Kindler S, Behrens F, Braun J, et al. Implementing an automated monitoring process in a digital, longitudinal observational cohort study. Arthritis Res Ther. 2021;23(1):181.","journal-title":"Arthritis Res Ther"},{"key":"3650_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s41073-016-0007-6","volume":"1","author":"S Heidari","year":"2016","unstructured":"Heidari S, Babor TF, De Castro P, Tort S, Curno M. Sex and gender equity in research: rationale for the SAGER guidelines and recommended use. Res Integr Peer Rev. 2016;1:2.","journal-title":"Res Integr Peer Rev"},{"issue":"7","key":"3650_CR16","doi-asserted-by":"publisher","first-page":"e61","DOI":"10.1136\/annrheumdis-2018-213548","volume":"78","author":"MM Schoels","year":"2019","unstructured":"Schoels MM, Smolen JS, Aletaha D. To DAPSA or not to DAPSA? That is not the question. Ann Rheum Dis. 2019;78(7):e61.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"3650_CR17","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1002\/acr.22456","volume":"67","author":"BR England","year":"2015","unstructured":"England BR, Sayles H, Mikuls TR, Johnson DS, Michaud K. Validation of the rheumatic disease comorbidity index. Arthritis Care Res (Hoboken). 2015;67(6):865\u201372.","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"3650_CR18","doi-asserted-by":"crossref","unstructured":"Stouten V, Pazmino S, Verschueren P, Mamouris P, Westhovens R, de Vlam K et al. Comorbidity burden in the first three years after diagnosis in patients with rheumatoid arthritis, psoriatic arthritis or spondyloarthritis: a general practice registry-based study. RMD Open. 2021;7(2).","DOI":"10.1136\/rmdopen-2021-001671"},{"issue":"3","key":"3650_CR19","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1159\/000376585","volume":"84","author":"CW Topp","year":"2015","unstructured":"Topp CW, \u00d8stergaard SD, S\u00f8ndergaard S, Bech P. The WHO-5 Well-Being index: a systematic review of the literature. Psychother Psychosom. 2015;84(3):167\u201376.","journal-title":"Psychother Psychosom"},{"issue":"1","key":"3650_CR20","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s13075-023-03127-2","volume":"25","author":"A Reich","year":"2023","unstructured":"Reich A, Wei\u00df A, Lindner L, Baraliakos X, Poddubnyy D, Zinke S, et al. Depressive symptoms are associated with fatigue, poorer functional status and less engagement in sports in AxSpA and psa: an analysis from the RABBIT-SpA cohort. Arthritis Res Ther. 2023;25(1):136.","journal-title":"Arthritis Res Ther"},{"issue":"41","key":"3650_CR21","first-page":"681","volume":"120","author":"T T\u00f6nnies","year":"2023","unstructured":"T\u00f6nnies T, Schlesinger S, Lang A, Kuss O. Mediation analysis in medical research. Dtsch Arztebl Int. 2023;120(41):681\u20137.","journal-title":"Dtsch Arztebl Int"},{"issue":"2","key":"3650_CR22","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1108\/JCP-02-2015-0010","volume":"5","author":"JN Miles","year":"2015","unstructured":"Miles JN, Kulesza M, Ewing B, Shih RA, Tucker JS, D\u2019Amico EJ. Moderated mediation analysis: an illustration using the association of gender with delinquency and mental health. J Crim Psychol. 2015;5(2):99\u2013123.","journal-title":"J Crim Psychol"},{"issue":"12","key":"3650_CR23","doi-asserted-by":"publisher","first-page":"e716","DOI":"10.1016\/S2665-9913(23)00264-3","volume":"5","author":"L Eder","year":"2023","unstructured":"Eder L, Mylvaganam S, Pardo Pardo J, Petkovic J, Strand V, Mease P, et al. Sex-related differences in patient characteristics, and efficacy and safety of advanced therapies in randomised clinical trials in psoriatic arthritis: a systematic literature review and meta-analysis. Lancet Rheumatol. 2023;5(12):e716\u201327.","journal-title":"Lancet Rheumatol"},{"issue":"4","key":"3650_CR24","doi-asserted-by":"publisher","first-page":"e112","DOI":"10.1097\/JW9.0000000000000112","volume":"9","author":"A Gonzalez-Cantero","year":"2023","unstructured":"Gonzalez-Cantero A, Constantin MM, Dattola A, Hillary T, Kleyn E, Magnolo N. Gender perspective in psoriasis: a scoping review and proposal of strategies for improved clinical practice by European dermatologists. Int J Womens Dermatol. 2023;9(4):e112.","journal-title":"Int J Womens Dermatol"},{"issue":"3","key":"3650_CR25","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1007\/s12016-018-8702-3","volume":"55","author":"A Blauvelt","year":"2018","unstructured":"Blauvelt A, Chiricozzi A. The Immunologic role of IL-17 in psoriasis and psoriatic arthritis pathogenesis. Clin Rev Allergy Immunol. 2018;55(3):379\u201390.","journal-title":"Clin Rev Allergy Immunol"},{"key":"3650_CR26","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, Aletaha D, Baraliakos X, Bertheussen H et al. EULAR recommendations for the management of psoriatic arthritis with Pharmacological therapies: 2023 update. Ann Rheum Dis. 2024:ard\u20132024."},{"issue":"9","key":"3650_CR27","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1093\/rheumatology\/key140","volume":"57","author":"P H\u00f8jgaard","year":"2018","unstructured":"H\u00f8jgaard P, Ballegaard C, Cordtz R, Zobbe K, Clausen M, Glintborg B, et al. Gender differences in biologic treatment outcomes-a study of 1750 patients with psoriatic arthritis using Danish health care registers. Rheumatology (Oxford). 2018;57(9):1651\u201360.","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"3650_CR28","doi-asserted-by":"publisher","first-page":"2663","DOI":"10.1007\/s10067-020-05027-1","volume":"39","author":"L Navarini","year":"2020","unstructured":"Navarini L, Costa L, Tasso M, Chimenti MS, Currado D, Fonti GL, et al. Retention rates and identification of factors associated with anti-TNF\u03b1, anti-IL17, and anti-IL12\/23R agents discontinuation in psoriatic arthritis patients: results from a real-world clinical setting. Clin Rheumatol. 2020;39(9):2663\u201370.","journal-title":"Clin Rheumatol"},{"issue":"10","key":"3650_CR29","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.1093\/rheumatology\/kead089","volume":"62","author":"AWR Van Kuijk","year":"2023","unstructured":"Van Kuijk AWR, Nurmohamed MT, Siebert S, Bergmans P, de Vlam K, Gremese E, et al. Gender-specific differences in patients with psoriatic arthritis receiving ustekinumab or tumour necrosis factor inhibitor: real-world data. Rheumatology (Oxford). 2023;62(10):3382\u201390.","journal-title":"Rheumatology (Oxford)"},{"key":"3650_CR30","doi-asserted-by":"publisher","first-page":"100188","DOI":"10.1016\/j.eclinm.2019.10.001","volume":"17","author":"S Watson","year":"2019","unstructured":"Watson S, Caster O, Rochon PA, den Ruijter H. Reported adverse drug reactions in women and men: aggregated evidence from globally collected individual case reports during half a century. EClinicalMedicine. 2019;17:100188.","journal-title":"EClinicalMedicine"},{"key":"3650_CR31","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s12875-016-0440-0","volume":"17","author":"AE Thompson","year":"2016","unstructured":"Thompson AE, Anisimowicz Y, Miedema B, Hogg W, Wodchis WP, Aubrey-Bassler K. The influence of gender and other patient characteristics on health care-seeking behaviour: a QUALICOPC study. BMC Fam Pract. 2016;17:38.","journal-title":"BMC Fam Pract"},{"issue":"10","key":"3650_CR32","doi-asserted-by":"publisher","first-page":"1913","DOI":"10.1111\/jdv.15733","volume":"33","author":"LS van der Schoot","year":"2019","unstructured":"van der Schoot LS, van den Reek J, Groenewoud JMM, Otero ME, Njoo MD, Ossenkoppele PM, et al. Female patients are less satisfied with biological treatment for psoriasis and experience more side-effects than male patients: results from the prospective biocapture registry. J Eur Acad Dermatol Venereol. 2019;33(10):1913\u201320.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6","key":"3650_CR33","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1080\/14740338.2023.2181340","volume":"22","author":"HR Gosselt","year":"2023","unstructured":"Gosselt HR, van Lint JA, Kosse LJ, Spuls PI, Vonkeman HE, Tas SW, et al. Sex differences in adverse drug reactions from adalimumab and etanercept in patients with inflammatory rheumatic diseases. Expert Opin Drug Saf. 2023;22(6):501\u20137.","journal-title":"Expert Opin Drug Saf"}],"updated-by":[{"DOI":"10.1186\/s13075-026-03820-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000}}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03650-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-025-03650-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-025-03650-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T07:59:01Z","timestamp":1779350341000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13075-025-03650-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,2]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3650"],"URL":"https:\/\/doi.org\/10.1186\/s13075-025-03650-4","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,2]]},"assertion":[{"value":"9 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1186\/s13075-026-03820-y","URL":"https:\/\/doi.org\/10.1186\/s13075-026-03820-y","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RABBIT-SpA is approved by the Ethics Committee of Charit\u00e9 University Medicine, Berlin (#EA1\/246\/16). Participants have to consent to participate in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LL: The author declares that they have no competing interests. AW: The author declares that they have no competing interests. AR: The author declares that they have no competing interests. CB: The author declares that they have no competing interests. FB: grants\/research support from Bionorica, Bristol Myers Squibb, Chugai, Iron4u, Janssen-Cilag, LEO Pharma, Novartis, Pfizer, and Roche andmeeting support, honoraria, or fees for serving as a speaker, consultant, and\/or advisory board member from AbbVie, Affibody, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly, Galapagos, GSK, Janssen-Cilag, MoonLake, Merck Sharp & Dohme, Novartis, Pfizer, Sandoz, Sanofi , and UCB. XB: Consultant, Scientific Advisory Board: Abbvie, Advanz, Alexion, Alphasigma, Amgen, AstraZeneca, BMS, Cesas, Celltrion, Clarivate, Galapagos, J&J, Lilly, Moonlake, Novartis, Peervoice, Pfizer, Roche, Sandoz, Springer, Stada, Takeda, UCB, Zuellig. Research Grants: Abbvie, Celltrion, Janssen, Moonlake, Novartis. Non-commercial disclosures: ASAS Past President, EULAR President-Elect. ACR: Speaker fees from Amgen, BMS, Novartis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"188"}}